MERCURY PHARMA GROUP LIMITED

1. MERCURY PHARMA GROUP LIMITED 2012-03-20 → present
2. GOLDSHIELD GROUP LIMITED 2010-01-15 → 2012-03-20
3. GOLDSHIELD GROUP PLC 1998-05-08 → 2010-01-04
4. GOLDSHIELD PHARMACEUTICALS (EUROPE) LIMITED 1992-07-02 → 1998-05-08
5. GOLDCREST PHARMACEUTICALS (EUROPE) LIMITED 1989-09-26 → 1992-07-02
6. SETBIT LIMITED 1988-12-23 → 1989-09-26

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102 (FRS 101)

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations as they fall due. In assessing the ability of the Company to continue as a going concern, the directors have taken account of the loss in 2024 of £21,695, the cumulative profits of £185,600, and the Company's net current assets and net asset position of £128,225 and £1,153,996, respectively at 31 December 2024. The Company's Intermediate Holding Company, APHL has provided the Company with a letter of support indicating its intention to provide the financial support required for a period of at least 12 months from the date these financial statements are approved. The Group's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the Group should be able to operate with the availability of cash and cash equivalents and intercompany arrangement. After making enquiries, considering the Company's forecasts and projections and considering the letter of support received from APHL, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the directors consider it appropriate to prepare these entity financial statements on a going concern basis.”

Group structure

1. MERCURY PHARMA GROUP LIMITED · parent
   1. Mercury Pharmaceuticals Limited 100% · United Kingdom · Marketing, and distribution of pharmaceutical and healthcare products
   2. Advanz Pharma Services (UK) Limited 100% · United Kingdom · Management Services
   3. Abcur AB 100% · Sweden · Marketing of pharmaceutical products
   4. Advanz Pharma Services (India) Private Limited 0.01% · India · Management Services
   5. Mercury Pharmaceuticals (Ireland) Limited 100% · Ireland · Marketing and distribution of pharmaceutical products
   6. Advanz Pharma Generics (UK) Limited 100% · United Kingdom · Marketing of pharmaceutical products
   7. Amdipharm UK Limited 100% · United Kingdom · Marketing of pharmaceutical products
   8. Boucher & Muir Pty Limited 28% · Australia · Marketing and distribution of pharmaceutical products
   9. Amdipharm Mercury Midco UK Limited 100% · United Kingdom · Marketing of pharmaceutical products
   10. Focus Pharmaceuticals Limited 100% · United Kingdom · Marketing and distribution of pharmaceutical products
   11. Advanz Pharma (Australia) Pty Limited 100% · Australia · Marketing and distribution of pharmaceutical products
   12. Amdipharm Limited 100% · Ireland · Marketing and distribution of pharmaceutical products
   13. Amdipharm Mercury (Hong Kong) Limited 100% · Hong Kong · Marketing and distribution of pharmaceutical products
   14. Advanz Pharma Switzerland Sarl 100% · Switzerland · Marketing and distribution of pharmaceutical products
   15. Advanz Pharma Germany GmbH 100% · Germany · Marketing and distribution of pharmaceutical products
   16. Advanz Pharma Italia S.R.L 100% · Italy · Marketing and distribution of pharmaceutical products
   17. Correvio S.A.S 100% · France · Marketing and distribution of pharmaceutical products
   18. Advanz Pharma Spain S.L.U 100% · Spain · Marketing and distribution of pharmaceutical products
   19. Advanz Pharma Belgium Sprl 100% · Belgium · Management services
   20. Correvio (Australia) Pty Ltd 100% · Australia · Management services
   21. Correvio (UK) Ltd 100% · United Kingdom · Management services
   22. Advanz Pharma Canada Inc 100% · Canada · Marketing and distribution of pharmaceutical products
   23. Advanz Pharma Specialty Medicine Switzerland GmbH 100% · Switzerland · Marketing and distribution of pharmaceutical products
   24. Advanz Pharma France SAS 100% · France · Marketing and distribution of pharmaceutical products
   25. Advanz Pharma Specialty Medicine Deutschland GmbH 100% · Germany · Marketing and distribution of pharmaceutical products
   26. Advanz Pharma Portugal, Unipessoal Lda 100% · Portugal · Marketing and distribution of pharmaceutical products
   27. Advanz Pharma Österreich GmbH 100% · Austria · Management services
   28. Advanz Pharma Italia S.r.l 100% · Italy · Marketing and distribution of pharmaceutical products
   29. Advanz Pharma Europe Limited 100% · United Kingdom · Management services

Significant events

• “On 2 December 2024, the Company signed an exclusive agreement with Bayer Aktiengesellschaft to acquire the marketing authorizations, trademarks and all distribution and other commercial know-how relating to Progynova® and Cyclo-Progynova® in the Asia-Pacific region for a consideration of £57.6 million.”
• “On 12 July 2024, the Company signed an agreement with UCB Biopharma SRL to acquire the rights of Nootropil® and Atarax® for Europe and selected countries in Latin America and Asia-Pacific for a total consideration of £131.9 million.”
• “On 7 June 2024, the Company signed a license and supply agreement with Alvotech to commercialise a biosimilar candidate for Eylea®, including an upfront payment of £12.7 million and up to £38.8 million in milestones.”
• “On 3 November 2023, the Company signed an agreement with Bayer Aktiengesellschaft to acquire the global rights to Androcur® for consideration of £22.2 million, completed on 1 February 2024.”
• “On 27 June 2024, the European Medicines Agency's (“EMA") CHMP concluded its review of Ocaliva® (obeticholic acid) and recommended the revocation of its CMA in the European Union. Subsequently, on 2 September 2024, the EC adopted CHMP's recommendation, revoking the CMA for Ocaliva® across all EU Member States and the European Economic Area ("EEA"). On 12 December 2024, the Company filed an application to appeal the Suspension Revocation at the European Court of Justice.”
• “On 15 April 2025, the Company signed an exclusive license and supply agreement for a long-acting injectable specialty medicine in selected countries throughout Europe, including the UK, as well as in Australia.”
• “On 28 May 2025, the Company signed a license and supply agreement with Alvotech to commercialize three biosimilar candidates in Europe, including an upfront payment of €50 million.”
• “On 16 June 2025, the Company signed an exclusive agreement with Bayer Aktiengesellschaft to acquire the marketing authorizations, trademarks and all distribution and other commercial know-how relating to Testoviron® (testosterone enantate) for Europe and selected markets in Latin America, the Middle East & Africa, and Asia-Pacific.”
• “On 30 June 2025, the Company signed a license and supply agreement with Alvotech to commercialize one more biosimilar candidate to Cimzia® (certolizumab pegol) in Europe, including an upfront payment of €10 million.”
• “20mcg Liothyronine tablets: On 10 October 2016, the UK Competition and Markets Authority ("CMA") commenced an investigation into ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") in relation to the pricing of liothyronine tablets in the UK by ADVANZ PHARMA during the period 2007-2017. The CMA decision imposed various fines for the parties involved, including fines of £40.9 million for ADVANZ PHARMA companies. On 8 August 2023, CAT issued its judgment which upheld the CMA decision against the Company and the Group. On 8 May 2025, the Court of Appeal issued its judgment in which it upheld the CMA's findings against the Company and the Group. So called "follow-on claims" for reimbursement of alleged losses, related to infringement of competition law, may arise when decisions and fines are issued by the CMA. In February 2023, the Department of Health informed the Company and the Group that it is likely to pursue follow on damages claims in the event that the CMA decision is upheld on appeal.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

1

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -10%

  £314,294,000 → £282,881,000

• Cash

  -84.8%

  £11,371,000 → £1,730,000

• Net assets

  -1.8%

  £1,175,691,000 → £1,153,996,000

• Employees

  +6.6%

  106 → 113

• Operating profit

  -146.6%

  £94,912,000 → -£44,236,000

• Profit before tax

  -126.5%

  £123,693,000 → -£32,742,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers